212 related articles for article (PubMed ID: 16239912)
41. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
Hillmen P; Skotnicki AB; Robak T; Jaksic B; Dmoszynska A; Wu J; Sirard C; Mayer J
J Clin Oncol; 2007 Dec; 25(35):5616-23. PubMed ID: 17984186
[TBL] [Abstract][Full Text] [Related]
42. Advances in the use of alemtuzumab in CLL.
Stilgenbauer S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
[No Abstract] [Full Text] [Related]
43. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
[TBL] [Abstract][Full Text] [Related]
44. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
45. Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil.
Prescrire Int; 2009 Apr; 18(100):60. PubMed ID: 19585719
[TBL] [Abstract][Full Text] [Related]
46. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
[TBL] [Abstract][Full Text] [Related]
47. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
Thieblemont C; Bouafia F; Hornez E; Dumontet C; Tartas S; Antal D; Lemieux B; Traullé C; Espinouse D; Salles G; Coiffier B
Leuk Lymphoma; 2004 Apr; 45(4):711-4. PubMed ID: 15160944
[TBL] [Abstract][Full Text] [Related]
48. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Osterborg A
Blood; 2002 Aug; 100(3):768-73. PubMed ID: 12130484
[TBL] [Abstract][Full Text] [Related]
49. Alemtuzumab.
Williamson TS
Clin J Oncol Nurs; 2001; 5(6):287-8. PubMed ID: 11899633
[No Abstract] [Full Text] [Related]
50. Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
Kharfan-Dabaja MA; Fahed R; Hussein M; Santos ES
Expert Opin Investig Drugs; 2007 Nov; 16(11):1799-815. PubMed ID: 17970639
[TBL] [Abstract][Full Text] [Related]
51. Successful treatment of steroid resistant autoimmune thrombocytopenia associated with chronic lymphocytic leukemia with alemtuzumab.
Ammatuna E; Marino C; Mitra ME; Calvaruso G; Iannitto E
Eur J Haematol; 2004 Sep; 73(3):225-6. PubMed ID: 15287923
[No Abstract] [Full Text] [Related]
52. Monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
Liu NS; O'Brien S
Med Oncol; 2004; 21(4):297-304. PubMed ID: 15579912
[TBL] [Abstract][Full Text] [Related]
53. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.
Fiegl M; Erdel M; Tinhofer I; Brychtova Y; Panovska A; Doubek M; Eigenberger K; Fonatsch C; Hopfinger G; Mühlberger H; Zabernigg A; Falkner F; Gastl G; Mayer J; Greil R;
Ann Oncol; 2010 Dec; 21(12):2410-2419. PubMed ID: 20466745
[TBL] [Abstract][Full Text] [Related]
54. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
Lee D
Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
[No Abstract] [Full Text] [Related]
55. Taking the measure of alemtuzumab.
Gilleece MH
Leuk Res; 2004 Dec; 28(12):1253-4. PubMed ID: 15475064
[No Abstract] [Full Text] [Related]
56. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
Thompson CA
Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
[No Abstract] [Full Text] [Related]
57. Update on monoclonal antibody therapy in chronic lymphocytic leukemia.
Zent CS; Kay NE
Clin Adv Hematol Oncol; 2004 Feb; 2(2):107-13. PubMed ID: 16163170
[TBL] [Abstract][Full Text] [Related]
58. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia.
Hohwy T; Bang K; Steiniche T; Peterslund NA; d'Amore F
Eur J Haematol; 2004 Sep; 73(3):206-9. PubMed ID: 15287918
[TBL] [Abstract][Full Text] [Related]
59. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.
Fiegl M; Stauder R; Steurer M; Mian M; Hopfinger G; Brychtova Y; Skrabs C; Zabernigg A; Schmid F; Haslbaur F; Winder G; Walder A; Lang A; Voskova D; Greil R; Mayer J; Gastl G;
Ann Hematol; 2014 Feb; 93(2):267-77. PubMed ID: 24292560
[TBL] [Abstract][Full Text] [Related]
60. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.
Nabhan C; Dyer MJ; Rosen ST
Oncology (Williston Park); 2003 Feb; 17(2):253-62; discussion 264, 267, passim. PubMed ID: 12632866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
